Mr. Peter Rubinstein - GeneType | Genetic Technologies

Mr. Peter Rubinstein

BEc, LLB
Chairman - Non – Executive Director

Mr. Rubinstein was appointed to the Board on 31 January 2018 and appointed as Chairman in April 2020. He has over 20 years of experience in early-stage technology commercialisation through to public listings on the ASX. He is a lawyer, having worked at a large national firm prior to moving in-house at Montech, the commercial arm of Monash University. Mr. Rubinstein has had significant exposure to the creation, launch, and management of a diverse range of technology companies in biotech, digital payments, and renewable energy. Mr. Rubinstein is also a Non-Executive Director of DigitalX Limited (ASX: DCC).